Hypertension, antihypertensive drugs, and age at onset of Huntington’s disease

Abstract Background Associations between blood pressure (BP) with age at onset of Huntington’s disease (HD) have reported inconsistent findings. We used Mendelian randomization (MR) to assess effects of BP and lowering systolic BP (SBP) via the genes encoding targets of antihypertensive drugs on age...

Full description

Bibliographic Details
Main Authors: Yahui Zhu, Mao Li, Jiongming Bai, Haoran Wang, Xusheng Huang
Format: Article
Language:English
Published: BMC 2023-05-01
Series:Orphanet Journal of Rare Diseases
Subjects:
Online Access:https://doi.org/10.1186/s13023-023-02734-1
_version_ 1797817803265277952
author Yahui Zhu
Mao Li
Jiongming Bai
Haoran Wang
Xusheng Huang
author_facet Yahui Zhu
Mao Li
Jiongming Bai
Haoran Wang
Xusheng Huang
author_sort Yahui Zhu
collection DOAJ
description Abstract Background Associations between blood pressure (BP) with age at onset of Huntington’s disease (HD) have reported inconsistent findings. We used Mendelian randomization (MR) to assess effects of BP and lowering systolic BP (SBP) via the genes encoding targets of antihypertensive drugs on age at onset of HD. Methods Genetic variants from genome-wide association studies(GWAS) of BP traits and BP-lowering variants in genes encoding antihypertensive drugs targets were extracted. Summary statistics for age at onset of HD were retrieved from the GWAS meta-analysis of HD residual age at onset from the GEM-HD Consortium included 9064 HD patients of European ancestry (4417 males and 4,647 females). MR estimates were calculated using the inverse variance weighted method, supplemented by MR-Egger, weighted median, and MR-PRESSO methods. Results Genetically predicted SBP or diastolic BP increase was associated with a later age at onset of HD. However, after SBP/DBP was present as a covariate using multivariable MR method, no significant causal association was suggested. A 10-mm Hg reduction in SBP through variants in genes encoding targets of calcium channel blockers (CCB) was associated with an earlier age at onset of HD (β=-0.220 years, 95% CI =-0.337 to -0.102, P = 2.42 × 10− 4). We did not find a causal association between angiotensin converting enzyme inhibitors and β-blockers with the earlier HD onset. No heterogeneity and horizontal pleiotropy were identified. Conclusions This MR analysis provided evidence that genetically determined SBP lowering through antihypertensive drugs might be associated with an earlier age at onset of HD. The results may have a potential impact on management of hypertension in the pre-motor-manifest HD population.
first_indexed 2024-03-13T08:58:52Z
format Article
id doaj.art-dd68f559f84c490d874b6ed79b7b3f06
institution Directory Open Access Journal
issn 1750-1172
language English
last_indexed 2024-03-13T08:58:52Z
publishDate 2023-05-01
publisher BMC
record_format Article
series Orphanet Journal of Rare Diseases
spelling doaj.art-dd68f559f84c490d874b6ed79b7b3f062023-05-28T11:27:24ZengBMCOrphanet Journal of Rare Diseases1750-11722023-05-0118111010.1186/s13023-023-02734-1Hypertension, antihypertensive drugs, and age at onset of Huntington’s diseaseYahui Zhu0Mao Li1Jiongming Bai2Haoran Wang3Xusheng Huang4Medical School of Chinese PLAMedical School of Chinese PLADepartment of Neurology, the First Medical Center, Chinese PLA General HospitalDepartment of Neurology, the First Medical Center, Chinese PLA General HospitalMedical School of Chinese PLAAbstract Background Associations between blood pressure (BP) with age at onset of Huntington’s disease (HD) have reported inconsistent findings. We used Mendelian randomization (MR) to assess effects of BP and lowering systolic BP (SBP) via the genes encoding targets of antihypertensive drugs on age at onset of HD. Methods Genetic variants from genome-wide association studies(GWAS) of BP traits and BP-lowering variants in genes encoding antihypertensive drugs targets were extracted. Summary statistics for age at onset of HD were retrieved from the GWAS meta-analysis of HD residual age at onset from the GEM-HD Consortium included 9064 HD patients of European ancestry (4417 males and 4,647 females). MR estimates were calculated using the inverse variance weighted method, supplemented by MR-Egger, weighted median, and MR-PRESSO methods. Results Genetically predicted SBP or diastolic BP increase was associated with a later age at onset of HD. However, after SBP/DBP was present as a covariate using multivariable MR method, no significant causal association was suggested. A 10-mm Hg reduction in SBP through variants in genes encoding targets of calcium channel blockers (CCB) was associated with an earlier age at onset of HD (β=-0.220 years, 95% CI =-0.337 to -0.102, P = 2.42 × 10− 4). We did not find a causal association between angiotensin converting enzyme inhibitors and β-blockers with the earlier HD onset. No heterogeneity and horizontal pleiotropy were identified. Conclusions This MR analysis provided evidence that genetically determined SBP lowering through antihypertensive drugs might be associated with an earlier age at onset of HD. The results may have a potential impact on management of hypertension in the pre-motor-manifest HD population.https://doi.org/10.1186/s13023-023-02734-1HypertensionAntihypertensive drugsHuntington’s diseaseMendelian randomization
spellingShingle Yahui Zhu
Mao Li
Jiongming Bai
Haoran Wang
Xusheng Huang
Hypertension, antihypertensive drugs, and age at onset of Huntington’s disease
Orphanet Journal of Rare Diseases
Hypertension
Antihypertensive drugs
Huntington’s disease
Mendelian randomization
title Hypertension, antihypertensive drugs, and age at onset of Huntington’s disease
title_full Hypertension, antihypertensive drugs, and age at onset of Huntington’s disease
title_fullStr Hypertension, antihypertensive drugs, and age at onset of Huntington’s disease
title_full_unstemmed Hypertension, antihypertensive drugs, and age at onset of Huntington’s disease
title_short Hypertension, antihypertensive drugs, and age at onset of Huntington’s disease
title_sort hypertension antihypertensive drugs and age at onset of huntington s disease
topic Hypertension
Antihypertensive drugs
Huntington’s disease
Mendelian randomization
url https://doi.org/10.1186/s13023-023-02734-1
work_keys_str_mv AT yahuizhu hypertensionantihypertensivedrugsandageatonsetofhuntingtonsdisease
AT maoli hypertensionantihypertensivedrugsandageatonsetofhuntingtonsdisease
AT jiongmingbai hypertensionantihypertensivedrugsandageatonsetofhuntingtonsdisease
AT haoranwang hypertensionantihypertensivedrugsandageatonsetofhuntingtonsdisease
AT xushenghuang hypertensionantihypertensivedrugsandageatonsetofhuntingtonsdisease